Insmed has announced that Chief Financial Officer Sara Bonstein will step down from her role on October 30, 2026, after nearly seven years with the biopharmaceutical company.
Bonstein will remain CFO through Insmed’s third-quarter 2026 financial reporting process and is expected to participate in the company’s earnings call on October 29.
Insmed has begun a search for its next CFO and has retained an executive search firm to assist with the process.
The company said Bonstein’s departure is not related to any disagreement involving Insmed’s accounting practices, financial statements, internal controls or operations.
During Bonstein’s tenure, Insmed raised more than $4.2 billion in capital.
The company said it is now positioned to reach cash flow positivity in 2027 and believes it has a path toward sustained revenue growth and profitability.
Insmed has undergone a broader transformation into a diversified global biotechnology company with a portfolio of commercial and pipeline therapies.
The company highlighted the launch of BRINSUPRI and continued commercial performance of ARIKAYCE as important components of that strategy.
Alongside the CFO transition, Insmed reaffirmed its full-year 2026 financial guidance.
The company continues to expect BRINSUPRI revenue of between $1.25 billion and $1.40 billion for the year.
ARIKAYCE revenue is expected to range from $450 million to $470 million.
Insmed plans to report third-quarter 2026 results on October 29 and will host an investor conference call that morning.
The company said its search for a new CFO will focus on identifying an executive capable of supporting Insmed’s next phase as its commercial portfolio and development pipeline expand.
KEY QUOTES:
“We are grateful for Sara’s many contributions over the past almost seven years and her dedicated leadership overseeing our finance organization during a time when Insmed raised more than $4.2 billion in capital. We are now well positioned to reach cash flow positivity next year with what we view as a clear path toward sustained top-line growth and bottom-line profitability.”
“Sara has been a steadfast partner in building Insmed into the company we are today, and we wish her well as she pursues her next leadership opportunity. Insmed has undergone a major transformation in recent years to become a global diversified biotech company with a robust portfolio of first- or best-in-class therapies with the potential to deliver meaningful impact for patients with serious diseases. With BRINSUPRI and ARIKAYCE on track to deliver meaningful revenue this year, and with substantial growth expected in the years ahead through our commercial portfolio and diverse therapeutic pipeline, we remain focused on delivering on our long-term ambitions. We are committed to ensuring our finance operations continue supporting Insmed’s success in our next phase of growth, and we have partnered with a leading executive search firm to identify our next CFO.”
Will Lewis, Chair and Chief Executive Officer of Insmed
“Serving as Insmed’s CFO has been a privilege of my career. I am thankful for our team and all we achieved together during my time with the Company. I am confident in Insmed’s future, especially given our successful launch of BRINSUPRI coupled with our exciting pipeline. After considerable reflection, now is an ideal time for me to pursue my ambition for a broader leadership role.”
Sara Bonstein, Chief Financial Officer of Insmed
